FDA grants Breakthrough Therapy Designation for the company's treatment of Sanfilippo Syndrome, a rare neurodegenerative disorder.
Shares jump over 8% after billionaire Philippe Laffont's firm reveals a significant investment, signaling renewed institutional confidence in the hydrogen sector.
The bank raised its price target to $220 from $160, citing 'sold out' high-bandwidth memory as a key catalyst for future growth.
FDA grants Breakthrough Therapy Designation to the company's drug for a rare, fatal pediatric disorder, paving the way for accelerated review and potential approval.
Ascendiant Capital Markets reiterates a 'Buy' rating, citing significant undervaluation and projecting a potential 1,460% upside for the e-commerce firm.
Shares surged in after-hours trading after the company revealed positive results for its lead drug candidate, Telomir-1, in age-related studies.
The fund, BGTF II, is now the world's largest private fund dedicated to clean energy and decarbonization, signaling strong investor confidence.
Nimacimab monotherapy misses primary weight-loss endpoint, though combination with semaglutide shows promise, raising questions for the drug's future.